Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1

Lignende værker

• Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
  af: Mateos, María-Victoria, et al.
  Udgivet: (2017)
• Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
  af: Kaiser, Martin, et al.
  Udgivet: (2020)
• New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib
  af: Richardson, Paul G, et al.
  Udgivet: (2017)
• Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
  af: Kaiser, Martin, et al.
  Udgivet: (2020)
• Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
  af: Kumar, Shaji, et al.
  Udgivet: (2017)